ZD6474 and Docetaxel in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Collaborators:
Jonsson Comprehensive Cancer Center
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00054093
First received: February 5, 2003
Last updated: April 7, 2011
Last verified: April 2011

February 5, 2003
April 7, 2011
November 2002
September 2004   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00054093 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
ZD6474 and Docetaxel in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Multicenter, Phase II Study To Assess The Safety, Tolerability, And Efficacy Of ZD6474 In Combination With Docetaxel (TAXOTERE) In Subjects With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure Of Prior Platinum-Based Chemotherapy

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ZD6474 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

PURPOSE: Randomized phase II trial to compare the effectiveness of different regimens of ZD6474 combined with docetaxel in treating patients who have locally advanced or metastatic non-small cell lung cancer that is refractory to platinum-based chemotherapy.

OBJECTIVES:

  • Compare the efficacy of ZD6474 and docetaxel vs docetaxel and placebo, in terms of progression-free survival, in patients with locally advanced or metastatic non-small cell lung cancer refractory to platinum-based chemotherapy.
  • Compare the tolerability and safety of these regimens, in terms of incidence and nature of adverse effects and electrocardiogram changes, in these patients.
  • Compare the objective response rate and duration of response of patients treated with these regimens.
  • Compare the pharmacokinetics of these regimens in these patients.
  • Compare the overall survival of patients treated with these regimens.
  • Compare objective tumor response and progression-free survival with the biological assessment of these regimens in these patients.
  • Compare quality of life, lung cancer symptoms, and performance status of patients treated with these regimens.

OUTLINE: This is a multicenter, two-phase study comprising an open-label phase followed by a double-blind, randomized phase.

  • Open-label phase: Patients receive docetaxel IV over 1 hour on day 1 and oral ZD6474 once daily beginning on day 2. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
  • Randomized phase: Patients are randomized to 1 of 3 treatment arms.

    • Arm I: Patients receive docetaxel IV over 1 hour on day 1 and oral ZD6474 once daily beginning on day 1.
    • Arm II: Patients receive docetaxel as in arm I and ZD6474 as in arm I but at a higher dose.
    • Arm III: Patients receive docetaxel as in arm I and oral placebo once daily beginning on day 1.

In all arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, after the first 4 courses, and then after every other course thereafter.

Patients are followed at 30 days and then every 6 weeks thereafter.

PROJECTED ACCRUAL: A total of 129 patients (9 patients for the open-label phase, 120 patients [40 per treatment arm] for the randomized phase) will be accrued for this study within approximately 8 months (3 months for the open-label phase, 5 months for the randomized phase).

Interventional
Phase 2
Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer
  • Drug: docetaxel
  • Drug: vandetanib
Not Provided
Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007 Sep 20;25(27):4270-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
107
December 2007
September 2004   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed non-small cell lung cancer

    • Locally advanced or metastatic disease (stage IB-IV)
    • No mixed small cell histology
    • No bronchoalveolar carcinoma
  • Failed first-line platinum-based chemotherapy
  • At least one unidimensionally measurable lesion

    • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • No brain metastases or spinal cord compression unless treated at least 4 weeks before study and stable without steroids for at least 1 week

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • WHO 0-1

Life expectancy

  • At least 12 weeks

Hematopoietic

  • Neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic

  • Bilirubin no greater than upper limit of normal (ULN)
  • AST and ALT no greater than 1.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN
  • No hepatitis B

Renal

  • Creatinine no greater than 1.5 times ULN
  • Calcium (adjusted for albumin) normal

Cardiovascular

  • No significant cardiovascular disease
  • No symptomatic heart failure or angina within the past 3 months
  • No cardiac disease that increases risk of a ventricular arrhythmia
  • No clinically significant arrhythmia (e.g., multifocal premature ventricular contractions, bigeminy, trigeminy, or ventricular tachycardia) that is symptomatic or requires treatment
  • No symptomatic sustained ventricular tachycardia
  • No chronic atrial fibrillation
  • No history of QT prolongation with other medications
  • No congenital long QT syndrome
  • No QTc with Bazett's correction unmeasurable or more than 460 msec by screening electrocardiogram
  • LVEF at least 45% by MUGA (for patients with prior anthracycline therapy with total dose greater than 450 mg/m^2)

Pulmonary

  • Oxygen saturation at least 90% on room air
  • No requirement for supplemental oxygen

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-barrier contraception
  • No known hypersensitivity to drugs formulated with polysorbate 80
  • HIV negative
  • No severe or uncontrolled systemic disease
  • Magnesium normal
  • Potassium at least 4.0 meq/L

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • More than 6 weeks since prior suramin
  • No concurrent biological response modifiers (including cytokines)

Chemotherapy

  • See Disease Characteristics
  • Prior docetaxel or paclitaxel allowed
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

Endocrine therapy

  • See Disease Characteristics
  • No concurrent hormonal therapy for cancer

Radiotherapy

  • No prior chest radiotherapy
  • More than 4 weeks since other prior radiotherapy
  • No concurrent radiotherapy

Surgery

  • Not specified

Other

  • No prior agents that block the endothelial growth factor (EGF) or vascular EGF pathways
  • More than 4 weeks since prior systemic anticancer therapy
  • More than 4 weeks since prior investigational agents
  • More than 2 weeks since prior, and no concurrent, treatment with any of the following:

    • Amiodarone
    • Chlorpromazine
    • Ketoconazole
    • Itraconazole
    • Troleandomycin
    • Erythromycin
    • Diltiazem
    • Verapamil
    • Phenytoin
    • Carbamazepine
    • Rifampin
  • More than 4 weeks since prior barbiturates
  • More than 2 weeks since prior therapeutic-dose warfarin
  • No concurrent therapeutic-dose warfarin
  • No concurrent barbiturates
  • No concurrent medications known to affect QTc
  • No concurrent medications known to prolong QT interval or induce Torsade de Pointes
  • No other concurrent anticancer therapy
  • No other concurrent cytotoxic therapy for cancer
  • No other concurrent investigational agents
  • Low dose-warfarin for catheter clot prophylaxis allowed
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00054093
D4200C00006, UCLA-0208009, ZENECA-6474IL/0006, CDR0000269881
Not Provided
Not Provided
AstraZeneca
  • National Cancer Institute (NCI)
  • Jonsson Comprehensive Cancer Center
Principal Investigator: Diane Prager, MD Jonsson Comprehensive Cancer Center
AstraZeneca
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP